Physician profile
Jamie Easterling
NPI 1376194399
$4,668.01
in general payments reported to CMS, 2019-2025
39 companies · $1,025 in 2025
The $1,025 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $888 · 2022: $771 · 2023: $1,011 · 2024: $972 · 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,008.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,024.06 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $471.82 | 2021-2025 | Repatha, Otezla, Otezla |
| Dexcom, INC. | $421.73 | 2022-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $398.50 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $343.12 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $155.54 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $152.12 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $143.53 | 2021-2024 | |
| Abbvie INC. | $137.22 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $117.40 | 2025 | Caplyta |
| Amarin Pharma, INC. | $111.12 | 2021-2022 | |
| Corcept Therapeutics | $92.67 | 2024-2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.58 | 2024-2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $77.43 | 2025 | Gemtesa |
| Lundbeck LLC | $72.68 | 2022-2023 | Vyepti |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $72.15 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Insulet Corporation | $67.10 | 2023-2024 | Omnipod |
| Optinose US, INC. | $65.82 | 2021 | |
| Daiichi Sankyo INC. | $65.05 | 2021-2023 | Injectafer |
| Astellas Pharma US INC | $58.30 | 2021-2025 | Veozah |
| Exact Sciences Corporation | $43.16 | 2023 | Cologuard Collection Kit |
| Alnylam Pharmaceuticals INC. | $42.86 | 2022-2023 | Onpattro |
| Xeris Pharmaceuticals, INC. | $37.55 | 2022-2023 | Keveyis |
| Esperion Therapeutics, INC. | $37.08 | 2021 | |
| Eisai INC. | $35.44 | 2021-2022 | |
| Edwards Lifesciences Corporation | $34.25 | 2022-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Biohaven Pharmaceutical Holding Company LTD. | $34.18 | 2022 | |
| Renalytix Ai, INC. | $34.17 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $32.77 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.12 | 2021-2025 | Jardiance |
| Abbott Laboratories | $28.70 | 2025 | Freestyle Libre 3 |
| Boston Scientific Corporation | $25.19 | 2023 | |
| Genentech USA, INC. | $19.36 | 2021 | |
| Sanofi Pasteur INC. | $19.17 | 2025 | |
| Hologic Sales and Service, LLC | $19.15 | 2024 | Aptima, Thinprep 2000 Processor |
| Seqirus USA INC | $16.74 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Stryker Corporation | $15.68 | 2025 | Clottriever Bold Catheter |
| Idorsia Pharmaceuticals US INC | $13.90 | 2023 | Quviviq |
| Nestle Healthcare Nutrition INC. | $11.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Easterling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.